

February 14, 2022

**The Deputy General Manager
Dept of Corporate Services
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400001**

Dear Sir

Subject: **Outcome of Board Meeting.**

This is with reference to our letter dated 27th January 2022.

At the meeting of the Board of Directors of the Company held on 14th February 2022 the following decisions have been taken:

- 1) Approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the quarter ended 31st December 2021.
- 2) Approved the Licensing agreement between Transgene Biotech Limited and NiedlFree Technologies Pvt Ltd.

This is for your information and records.

Thanking you

Yours Sincerely

For **TRANSGENE BIOTEK LIMITED**



DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR
DIN NO:02287235

Encls: as above

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31,2021

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations	-	16,949	15,65,499	16,95,499
2	Other income (net)	4,38,470	4,38,470	5,10,627	26,68,984
3	Total income (1 + 2)	4,38,470	4,55,419	20,76,126	43,64,483
4	EXPENSES				
	Cost of materials consumed	1,29,752	31,639	64,684	6,08,280
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-
	Employee benefits expense	7,79,734	6,54,777	6,55,322	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,681	26,62,723
	Depreciation and amortisation expense	247,05,193	247,05,193	248,12,011	990,80,463
	Other expenses	6,87,341	5,24,922	10,43,125	38,85,247
	Total expenses	268,68,970	264,83,481	272,40,823	1086,95,949
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(264,30,500)	(260,28,062)	(251,64,697)	(1043,31,466)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(264,30,500)	(260,28,062)	(251,64,697)	(1043,31,466)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(264,30,500)	(260,28,062)	(251,64,697)	(1043,31,466)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(264,30,500)	(260,28,062)	(251,64,697)	(1043,31,466)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.35)	(0.34)	(0.33)	(1.38)
	Diluted (Rs.)	(0.35)	(0.34)	(0.33)	(1.38)

Notes:

- 1 "Nozulin" - Intra-Nasal delivery of Insulin: Necessary steps have been taken for getting regulatory approvals to complete all relevant studies for obtaining manufacturing and marketing license on "Nozulin".
- 2 No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
- 3 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th February 2022.

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director


Date: 14.02.2022

Place:Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Standalone financial statements****Other operating expenses**

Particulars	For the Period ended Dec 31,2021
Bank Charges	8
Business Promotional Expenses	1,387
Conveyance Charges	3,500
Directors sitting fee	15,000
Legal and Professional Charges	2,14,250
Miscellaneous Expenses	3,899
Office Expenses	5,860
Patents Application fees	-
Postage and courier	80
Power and Fuel	14,398
Rates, Taxes and Duties	21,600
SEBI Expenses	3,00,000
Telephone Charges	6,191
Website and Software expenses	16,390
Advertisement Exp	-
E Voting Charges	33,325
Transport Charges	4,500
Interest and Penalties	-
Insurance	39,908
Internet Charges	6,045
Repairs and Maintenance	1,000
Total	6,87,341

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao**
Managing Director

TRANSGENE BIOTEK LTD

FIXED ASSETS UP TO 31/12/2021 STANDALONE

Sl. No	PARTICULARS	DEPRN. RATE %	GROSS BLOCK				DEPRECIATION					NET BLOCK	
			AS AT 30.09.2021	Addition during the Period	(Deletion) during the Period	AS AT 31.12.2021	Up to 30.09.2021	Depreciation on Additions	Depreciation on Deletions	for the Period ended 31.12.2021	Up to 31.12.2021	AS AT 31.12.2021	AS AT 30.09.2021
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
1	Land	-	6,55,796	-	-	6,55,796	-	-	-	-	-	6,55,796	6,55,796
2	Building	3.34	340,19,720	-	-	340,19,720	219,31,943	-	-	65,592	219,97,534	120,22,186	120,87,777
3	Buildings temporary	100.00	68,163	-	-	68,163	68,163	-	-	-	68,163	-	-
4	Computers	16.21	18,75,513	-	-	18,75,513	17,54,930	-	-	3,146	17,58,076	1,17,437	1,20,583
5	Electrical Equipments	4.75	102,20,375	-	-	102,20,375	102,20,375	-	-	-	102,20,375	-	-
6	Furniture	6.33	9,22,627	-	-	9,22,627	8,48,013	-	-	-	8,48,013	74,614	74,614
7	Lab Equipment	4.75	19,582	-	-	19,582	1,398	-	-	233	1,631	17,951	18,184
8	Office Equipments	4.75	185,76,575	-	-	185,76,575	176,52,518	-	-	-	176,52,518	9,24,057	9,24,057
9	Plant & Machinery	4.75	778,67,443	-	-	778,67,443	725,29,792	-	-	3,73,229	729,03,021	49,64,422	53,37,651
10	Generator	4.75	3,13,154	-	-	3,13,154	1,53,479	-	-	1,942	1,55,422	1,57,732	1,59,675
11	Vehicles	9.50	6,35,801	-	-	6,35,801	6,07,468	-	-	-	6,07,468	28,333	28,333
	Total (A)		1451,74,749	-	-	1451,74,749	1257,68,079	-	-	4,44,142	1262,12,220	189,62,529	194,06,670
	Intangible Assets												
1	Intellectual Property Rights	10.00	-	-	-	-	-	-	-	-	-	-	-
2	Technology	7.07	9301,18,554	-	-	9301,18,554	7862,41,802	-	-	242,43,077	8104,84,879	1196,33,675	1438,76,752
3	Patents		7,56,803	-	-	7,56,803	2,36,322	-	-	17,974	2,54,296	5,02,507	5,20,481
	Capital Work in Progress-Buildings		-	-	-	-	-	-	-	-	-	-	-
	Total (B)		9193,53,810	-	-	9308,75,357	7864,78,124	-	-	242,61,051	8107,39,175	1201,36,182	1443,97,233
	Total (A+B)		10468,66,516	-	-	10760,50,106	9122,46,203	-	-	247,05,193	9369,51,396	1390,98,710	1638,03,903

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad.

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31,2021

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Audited)	31.03.2021 (Audited)
1	Revenue from operations		16,949	15,65,499	16,95,499
2	Other income (net)	4,38,470	4,38,470	5,10,627	26,68,984
3	Total income (1 + 2)	4,38,470	4,55,419	20,76,126	43,64,483
4	EXPENSES				
	Cost of materials consumed	1,32,752	31,639	64,684	6,08,280
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade		0	-	
	Employee benefits expense	7,79,734	6,54,777	6,55,322	24,59,236
	Finance costs	5,66,950	5,66,950	6,65,681	26,62,723
	Depreciation and amortisation expense	247,05,193	247,05,193	248,12,011	990,80,463
	Other expenses	6,84,341	5,30,133	10,43,125	39,00,618
	Total expenses	268,68,970	264,88,691	272,40,823	1087,11,320
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(264,30,500)	(260,33,272)	(251,64,697)	(1043,46,837)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(264,30,500)	(260,33,272)	(251,64,697)	(1043,46,837)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(264,30,500)	(260,33,272)	(251,64,697)	(1043,46,837)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(264,30,500)	(260,33,272)	(251,64,697)	(1043,46,837)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.35)	(0.34)	(0.33)	(1.38)
	Diluted (Rs.)	(0.35)	(0.34)	(0.33)	(1.38)

Notes:

- ¹ "Nozulin" - Intra-Nasal delivery of Insulin: Necessary steps have been taken for getting regulatory approvals to complete all relevant studies for obtaining manufacturing and marketing license on "Nozulin".
- ² No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
- ³ The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th February 2022.

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director



Date: 14.02.2022
Place: Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Consolidated financial statements****Other operating expenses**

Particulars	For the Period ended Dec 31,2021
Bank Charges	8
Business Promotional Expenses	1,387
Conveyance Charges	500
Directors sitting fee	15,000
Legal and Professional Charges	2,14,250
Miscellaneous Expenses	3,899
Office Expenses	5,860
Patents Application fees	
Postage and courier	80
Power and Fuel	14,398
Rates, Taxes and Duties	21,600
SEBI Expenses	3,00,000
Telephone Charges	6,191
Website and Software expenses	16,390
Advertisement Exp	
E Voting Charges	33,325
Transport Charges	4,500
Interest and Penalties	-
Insurance	39,908
Internet Charges	6,045
Repairs and Maintenance	1,000
Total	6,84,341

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao**
Managing Director

FIXED ASSETS UP TO 31/12/2021 Consolidated

TRANSGENE BIOTEK LTD

		Opening											
Sl. No	PARTICULARS	DEPRN. RATE %	GROSS BLOCK				DEPRECIATION				NET BLOCK	AS AT 30.09.2021	
			AS AT 30.09.2021	Addition during the Period	(Deletion) during the Period	AS AT 31.12.2021	Up to 30.09.2021	Depreciation on Additions	Depreciation on Deletions	for the Period ended 31.12.2021	Up to 31.12.2021		AS AT 31.12.2021
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.		Rs.
1	Land	-	6,55,796	-	-	6,55,796	-	-	-	-	-	6,55,796	6,55,796
2	Building	3.34	340,19,720	-	-	340,19,720	219,31,943	-	-	65,592	219,97,534	120,22,186	120,87,777
3	Buildings temporary	100.00	68,163	-	-	68,163	68,163	-	-	-	68,163	-	-
4	Computers	16.21	18,75,513	-	-	18,75,513	17,54,930	-	-	3,146	17,58,076	1,17,437	1,20,583
5	Electrical Equipments	4.75	102,20,375	-	-	102,20,375	102,20,375	-	-	-	102,20,375	-	-
6	Furniture	6.33	9,22,627	-	-	9,22,627	8,48,013	-	-	-	8,48,013	74,614	74,614
7	Lab Equipment	4.75	19,582	-	-	19,582	1,398	-	-	233	1,631	17,951	18,184
8	Office Equipments	4.75	185,76,575	-	-	185,76,575	176,52,518	-	-	-	176,52,518	9,24,057	9,24,057
9	Plant & Machinery	4.75	778,67,443	-	-	778,67,443	725,29,792	-	-	3,73,229	729,03,021	49,64,422	53,37,651
##	Generator	4.75	3,13,154	-	-	3,13,154	1,53,479	-	-	1,942	1,55,422	1,57,732	1,59,675
##	Vehicles	9.50	6,35,801	-	-	6,35,801	6,07,468	-	-	-	6,07,468	28,333	28,333
Total (A)			1451,74,749	-	-	1451,74,749	1257,68,079	-	-	4,44,142	1262,12,220	189,62,529	194,06,670
Intangible Assets													
1	Intellectual Property Rights	10.00	-	-	-	-	-	-	-	-	-		-
2	Technology	7.07	9301,18,554	-	-	9301,18,554	7862,41,802	-	-	242,43,077	8104,84,879	1196,33,675	1438,76,752
3	Patents		7,56,803	-	-	7,56,803	2,36,322	-	-	17,974	2,54,296	5,02,507	5,20,481
Capital Work in Progress-Buildings				-	-	-	-	-	-	-	-		
Total (B)			9193,53,810	-	-	9308,75,357	7864,78,124	-	-	242,61,051	8107,39,175	1201,36,182	1443,97,233
Total (A+B)			10468,66,516	-	-	10760,50,106	9122,46,203	-	-	247,05,193	9369,51,396	1390,98,710	1638,03,903

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director





Limited Review Report

To,

The Board of directors


M/s. Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 31 December 2021 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities


Name of the entity Relationship

- | | |
|--------------------------------|------------|
| 1. Transgene Biotek HK Limited | Subsidiary |
| 2. PerOral Bio Private Limited | Subsidiary |



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 31 December 2021, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FRN 010114S


Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 14.02.2022



**Unique Document Identification Number (UDIN) for this document is
22212664ABYGDP6245**



Limited review report

To,

The Board of directors

M/s. Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 31 December 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates

Chartered Accountants

FRN No. 010114S

Manisha Dubey

Proprietor

M No. 212664

Place: Hyderabad

Date: 14.02.2022

